Trials / Active Not Recruiting
Active Not RecruitingNCT05805501
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 199 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tobemstomig | Participants will receive IV tobemstomig Q3W. |
| DRUG | Tiragolumab | Participants will receive IV tiragolumab Q3W. |
| DRUG | Pembrolizumab | Participants will receive IV pembrolizumab Q3W. |
| DRUG | Axitinib | Participants will receive axitinib PO BID. |
Timeline
- Start date
- 2023-04-21
- Primary completion
- 2026-10-31
- Completion
- 2026-10-31
- First posted
- 2023-04-10
- Last updated
- 2026-02-12
Locations
43 sites across 9 countries: United States, Australia, China, France, Germany, Poland, South Korea, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05805501. Inclusion in this directory is not an endorsement.